S&P expects steady erosion in Big Pharma's credit profile in 2021 as new M&A deals roll in — but don't underestimate their underlying strength
S&P Global has taken a look at the dominant forces shaping the pharma market and come to the conclusion that there will be more downgrades …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
